JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on November 16, 2004; DOI: 10.1124/jpet.104.074195


0022-3565/05/3122-525-536$20.00
JPET 312:525-536, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.074195v1
312/2/525    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schneider-Stock, R.
Right arrow Articles by Gali-Muhtasib, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schneider-Stock, R.
Right arrow Articles by Gali-Muhtasib, H.

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

5-aza-Cytidine Is a Potent Inhibitor of DNA Methyltransferase 3a and Induces Apoptosis in HCT-116 Colon Cancer Cells via Gadd45- and p53-Dependent Mechanisms

Regine Schneider-Stock, Mona Diab-Assef, Astrid Rohrbeck, Charlotte Foltzer-Jourdainne, Carsten Boltze, Roland Hartig, Peter Schönfeld, Albert Roessner, and Hala Gali-Muhtasib

Departments of Pathology (R.S.S., A.R., C.B., A.R.), Immunology (R.H.), and Biochemistry (P.S.), Otto-von-Guericke University, Magdeburg, Germany; Department of Biology, American University of Beirut, Beirut, Lebanon (H.G.M., M.D.A.); and Institut National de la Santé et de la Recherche Médicale, Strasbourg, France (C.F.J.)

Methyltransferase inhibitors commonly used in clinical trials promote tumor cell death, but their detailed cytotoxic action is not yet fully understood. A deeper knowledge about their apotosis-inducing mechanisms and their interaction with DNA methyltransferases (DNMTs) DNMT1, DNMT3a, and DNMT3b might allow the design of more effective drugs with lower cytotoxicity. 5-aza-cytidine (5-aza-CR), a potent inhibitor of DNMT1, is known to induce demethylation and reactivation of silenced genes. In this study, we investigated the p53 dependence of apoptotic, cell cycle, and growth inhibitory effects of 5-aza-CR, as well as the influence on the expression level of DNMT1, DNMT3a, and DNMT3b in the colon cancer cell line HCT-116. Exposure to 5-aza-CR induced the up-regulation of genes promoting cell cycle arrest and DNA repair (p21WAF1 and GADD45) or apoptosis (p53, RIPK2, Bak1, caspase 5, and caspase 6). In parallel, there was a down-regulation of antiapoptotic Bcl2 protein and the G2/M-mediator cyclin B1. Co-incubation with pifithrin-alpha (PFT-{alpha}), a selective p53 inhibitor, restored GADD45, Bcl2, cyclin B1, and p21WAF1 expression levels and almost completely reversed the growth inhibitory, cell cycle, and apoptotic effects of 5-aza-CR. 5-aza-CR treatment caused global demethylation and reactivation of p16INK4 expression. There was a marked decrease in DNMT1 and DNMT3a mRNA expression, with PFT-{alpha} reversing these effects. However, 5-aza-CR treatment did not modulate DNMT3b expression. Our data demonstrate that 5-aza-CR action in HCT-116 is mediated by p53 and its downstream effectors p21WAF1 and GADD45. This is the first report to show a link between p53 and regulation of DNMT1 and de novo methyltransferase DNMT3a.


Received for publication July 13, 2004
Accepted November 9, 2004.

Address correspondence to: Dr. Regine Schneider-Stock, Department of Pathology, Division Molecular Genetics, Otto-von-Guericke University, Leipziger Str. 44, 39120 Magdeburg, Germany. E-mail: regine.schneider-stock{at}medizin.uni-magdeburg.de




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
T. Nakano, A. Katafuchi, M. Matsubara, H. Terato, T. Tsuboi, T. Masuda, T. Tatsumoto, S. P. Pack, K. Makino, D. L. Croteau, et al.
Homologous Recombination but Not Nucleotide Excision Repair Plays a Pivotal Role in Tolerance of DNA-Protein Cross-links in Mammalian Cells
J. Biol. Chem., October 2, 2009; 284(40): 27065 - 27076.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. Xiong and R. J. Epstein
Growth inhibition of human cancer cells by 5-aza-2'-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status
Mol. Cancer Ther., April 1, 2009; 8(4): 779 - 785.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. Ecke, F. Petry, A. Rosenberger, S. Tauber, S. Monkemeyer, I. Hess, C. Dullin, S. Kimmina, J. Pirngruber, S. A. Johnsen, et al.
Antitumor Effects of a Combined 5-Aza-2'Deoxycytidine and Valproic Acid Treatment on Rhabdomyosarcoma and Medulloblastoma in Ptch Mutant Mice
Cancer Res., February 1, 2009; 69(3): 887 - 895.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. A. Link, M. R. Baer, S. R. James, D. A. Jones, and A. R. Karpf
p53-Inducible Ribonucleotide Reductase (p53R2/RRM2B) Is a DNA Hypomethylation-Independent Decitabine Gene Target That Correlates with Clinical Response in Myelodysplastic Syndrome/Acute Myelogenous Leukemia
Cancer Res., November 15, 2008; 68(22): 9358 - 9366.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Gali-Muhtasib, D. Kuester, C. Mawrin, K. Bajbouj, A. Diestel, M. Ocker, C. Habold, C. Foltzer-Jourdainne, P. Schoenfeld, B. Peters, et al.
Thymoquinone Triggers Inactivation of the Stress Response Pathway Sensor CHEK1 and Contributes to Apoptosis in Colorectal Cancer Cells
Cancer Res., July 15, 2008; 68(14): 5609 - 5618.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S. S. Palii, B. O. Van Emburgh, U. T. Sankpal, K. D. Brown, and K. D. Robertson
DNA Methylation Inhibitor 5-Aza-2'-Deoxycytidine Induces Reversible Genome-Wide DNA Damage That Is Distinctly Influenced by DNA Methyltransferases 1 and 3B
Mol. Cell. Biol., January 15, 2008; 28(2): 752 - 771.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. C. Oakes, T. L. J. Kelly, B. Robaire, and J. M. Trasler
Adverse Effects of 5-Aza-2'-Deoxycytidine on Spermatogenesis Include Reduced Sperm Function and Selective Inhibition of de Novo DNA Methylation
J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1171 - 1180.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
Y. Shen, J. Chow, Z. Wang, and G. Fan
Abnormal CpG island methylation occurs during in vitro differentiation of human embryonic stem cells
Hum. Mol. Genet., September 1, 2006; 15(17): 2623 - 2635.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Mohapatra, B. Chu, X. Zhao, and W.J. Pledger
Accumulation of p53 and Reductions in XIAP Abundance Promote the Apoptosis of Prostate Cancer Cells
Cancer Res., September 1, 2005; 65(17): 7717 - 7723.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. M. Melnick, K. Adelson, and J. D. Licht
The Theoretical Basis of Transcriptional Therapy of Cancer: Can It Be Put Into Practice?
J. Clin. Oncol., June 10, 2005; 23(17): 3957 - 3970.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.